CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following ...

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains ...

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

With cases of avian influenza A(H5N1) continuing to rise among cattle and humans in the US, scientists and government health ...

Shares of Novavax declined after the company reaffirmed full-year revenue and fellow vaccine maker Moderna lowered its guidance. Novavax stock was down 7.3%, to $8.64, on Monday but is up about 89% ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.

Shares in CureVac have plummeted after a German court ruled that a patent it holds on mRNA-based COVID-19 vaccines was invalid. The validity of the patent is at the heart of patent litigation ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We recently published a list of 10 Firms Post Strong Gains Amid Wall Street Bloodbath. In this article, we are going to take ...